Login to Your Account

Tokai terminates pivotal prostate cancer trial; stock plummets

By Michael Fitzhugh
Staff Writer

Tuesday, July 26, 2016

Tokai Pharmaceuticals Inc. called off a pivotal phase III trial comparing its triple-acting prostate cancer drug, galeterone, to Xtandi (enzalutamide, Medivation Inc.) after a data monitoring committee determined the trial was unlikely to meet its primary endpoint.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription